PanDNA is the molecular technology that drives PancraGEN. It identifies cumulative DNA abnormalities in pancreatic cysts. Using well-established molecular markers, PanDNA can help inform patient management when used in the context of clinical features, imaging, and cytology results.

DNA Abnormalities:

Tumor Suppressor Gene Panel (Loss of Heterozygosity)

VHL, OGG13p
PTEN, MXI110q
TP5317p
SMAD4, DCC18q
CDKN2A9p
RNF43, NME117q
PSEN2, TFF121q
CMM1v1p
MCC, APC5q
NF222q

Oncogene (Point Mutations)

KRASCodons 12, 13
GNASCodon 201

Elevated DNA Quantity

Key Components of Report

  • Summary of Molecular Results
  • Specific Molecular Results
  • Details of molecular results and what they could mean in clinical context

Risk of Cancer